RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
California’s Los Altos Pharma has in-licensed greater China rights to a pain product in development from Sedor Pharma of Pennsylvania. Los Altos will have development, manufacturing and commercialization rights to Captisol-enabled™ (CE) Meloxicam. Sedor acquired rights to CE Meloxicam from Ligand Pharma, which applied its Captisol program to increase safety and bioavailability of the drug. Los Altos and Sedor will work to develop IM/IV CE-Meloxicam to treat acute post-surgery, trauma and cancer pain.
Source: China Biotoday
